Daniel Spratt, MD, of the University of Michigan Rogel Cancer Center, and colleagues performed a secondary analysis of the NRG Oncology/RTOG 9601 double-blind, placebo-controlled, randomized, phase 3 trial (NCT00002874). In the original trial conducted 1998 to 2003, men with adverse pathology (positive surgical margin or pathologic T3 disease) and a PSA of 0.2 to 4.0 ng/mL after RP were randomly assigned to salvage radiation treatment (SRT) plus the nonsteroidal antiandrogen bicalutamide (150 mg/d) or placebo for 2 years.
October 29, 2019
Long-Term Antiandrogen Therapy With Salvage Radiation May Up Death Risk
In a secondary analysis of NRG Oncology/RTOG 9601, men with a PSA of 0.2 to 1.5 ng/mL before salvage radiation had no significant survival benefit from long-term antiandrogen treatment.